IFNG and psoriasis: The intradermal administration of all groups of drugs did not cause obvious histopathological damage to the main organs, including the heart, liver, spleen, lung, and kidney in the mice (Figure 3C), demonstrating that IFNγ-sEVs do not cause systemic adverse effects when used for psoriasis therapy.